Giulia Ferrannini, Juan M Maldonado, Sohini Raha, Purnima Rao-Melacini, Rutaba Khatun, Charles Atisso, Linda Shurzinske, Hertzel C Gerstein, Lars Rydén, M Angelyn Bethel
Objectives . To assess whether the use of cardioprotective therapies for type 2 diabetes varies by gender and whether the risk of cardiovascular events is higher in women versus men in the REWIND trial, including an international type 2 diabetes patient population with a wide range of baseline risk. Design . Gender differences in baseline characteristics, cardioprotective therapy, and the achieved clinical targets at baseline and two years were analyzed. Hazards for cardiovascular outcomes (fatal/nonfatal stroke, fatal/nonfatal myocardial infarction, cardiovascular death, all-cause mortality, and heart failure hospitalization), in women versus men were analyzed using two Cox proportional hazard models, adjusted for randomized treatment and key baseline characteristics respectively...
December 2023: Scandinavian Cardiovascular Journal: SCJ